Navidea biopharmaceuticals announces research agreement with the university of pennsylvania evaluating tc99m tilmanocept as a prognostic marker for glioblastoma

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a sponsored research agreement with the university of pennsylvania (“penn”) for a project to evaluate the use of tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. the research is led by principal
NAVB Ratings Summary
NAVB Quant Ranking